Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02970318
Registration number
NCT02970318
Ethics application status
Date submitted
18/11/2016
Date registered
22/11/2016
Date last updated
28/05/2024
Titles & IDs
Public title
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Query!
Scientific title
A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia
Query!
Secondary ID [1]
0
0
2015-004454-17
Query!
Secondary ID [2]
0
0
ACE-CL-309
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Chronic Lymphocytic Leukemia
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Children's - Leukaemia & Lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Acalabrutinib (ACP-196)
Treatment: Drugs - Rituximab
Treatment: Drugs - Idelalisib
Treatment: Drugs - Bendamustine
Experimental: Acalabrutinib (ACP-196) - Acalabrutinib (ACP-196) Monotherapy
Active Comparator: Rituximab Plus Idelalisib or Bendamustine - Investigator's Choice of Rituximab Plus Idelalisib or Bendamustine
Treatment: Drugs: Acalabrutinib (ACP-196)
Acalabrutinib monotherapy
Treatment: Drugs: Rituximab
Rituximab in combination with idelalisib or bendamustine
Treatment: Drugs: Idelalisib
Idelalisib in combination with rituximab
Treatment: Drugs: Bendamustine
Bendamustine in combination with rituximab
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-free Survival (PFS) Per Independent Review Committee (IRC) Assessment
Query!
Assessment method [1]
0
0
To evaluate the efficacy of acalabrutinib monotherapy (Arm A) compared with idelalisib/rituximab or bendamustine/rituximab (Arm B) based on Independent Review Committee (IRC) assessment of progression-free survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria (Hallek 2008) with incorporation of the clarification for treatment-related lymphocytosis (Cheson 2012) hereafter referred to as IWCLL 2008 criteria in subjects with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). As planned and reported in the interim clinical study report (dated 17 July 2019), because the study did cross the boundary at interim analysis.
IRC assessments were discontinued after the interim analysis. All IRC-related efficacy analyses in this clinical study report were based on the interim analysis data cutoff date of 15 January 2019. All other efficacy analyses were based on the final analysis data cutoff date of 03 September 2021.
Query!
Timepoint [1]
0
0
IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up
Query!
Secondary outcome [1]
0
0
Progression-free Survival (PFS) Per Investigator Assessment
Query!
Assessment method [1]
0
0
PFS per investigator assessment based on the final analysis data cutoff date of 03 September 2021.
Query!
Timepoint [1]
0
0
From randomization date to date of disease progression or death due to any cause or data cutoff date on 03Sep2021, whichever came first, regardless of use of subsequent anticancer therapy, until 53 months of follow-up.
Query!
Secondary outcome [2]
0
0
IRC-assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 15 January 2019 From Interim Analysis
Query!
Assessment method [2]
0
0
IRC-assessed overall response rate (ORR) including complete response (CR), CR with incomplete blood count recovery (CRi) nodular PR (nPR), and Partial Response (PR)
Query!
Timepoint [2]
0
0
IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up
Query!
Secondary outcome [3]
0
0
Investigator Assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 03 September 2021
Query!
Assessment method [3]
0
0
IRC-assessed overall response rate (ORR) including complete response (CR), CR with incomplete blood count recovery (CRi) nodular PR (nPR), and Partial Response (PR)
Query!
Timepoint [3]
0
0
Investigator assessments were done from randomization date until date of death or date of exit from study or data cut off date on 03Sep2021, whichever came first, up to 53 months of follow-up.
Query!
Secondary outcome [4]
0
0
Overall Survival (OS)
Query!
Assessment method [4]
0
0
Overall Survival (OS) was based on data cutoff date of 03Sep2021
Query!
Timepoint [4]
0
0
From randomization date to date of death due to any cause, or date of study discontinuation, or date of data cutoff on 03Sep2021, whichever came first until 54 months of follow-up.
Query!
Secondary outcome [5]
0
0
Duration of Response (DOR) Per Independent Review Committee (IRC) Assessment Based on 15 January 2019 Data Cutoff From Interim Analysis.
Query!
Assessment method [5]
0
0
Duration of Response (DOR) is defined as from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of disease progression or death from any cause.
Query!
Timepoint [5]
0
0
IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up
Query!
Secondary outcome [6]
0
0
Duration of Response (DOR) Per Investigator Assessment Based on 03 September 2021 Data Cutoff
Query!
Assessment method [6]
0
0
Duration of Response (DOR) is defined as from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of disease progression or death from any cause.
Query!
Timepoint [6]
0
0
Investigator assessments were done from randomization date until date of death or study discontinuation or data cutoff date on 03Sep2021, whichever came first up to 53 months of follow-up.
Query!
Secondary outcome [7]
0
0
Time to Next Treatment (TTNT) Based on 03 September 2021 Data Cutoff
Query!
Assessment method [7]
0
0
Time to Next Treatment (TTNT) is defined as the time from date of randomization to date of institution of non-protocol-specified treatment for CLL (or first dose date of acalabrutinib for Arm B subjects crossing over to receive acalabrutinib) or death due to any cause, whichever comes first.
Query!
Timepoint [7]
0
0
From randomization date to start of non-protocol specified subsequent anticancer therapy for CLL or death due to any cause or study discontinuation or data cutoff date on 03Sep2021,, whichever came first up to 53 months of follow-up.
Query!
Eligibility
Key inclusion criteria
1. Men and women = 18 years of age.
2. ECOG performance status of 0 to 2.
3. Diagnosis of CLL that meets published diagnostic criteria (Hallek 2008):
1. Monoclonal B-cells (either kappa or lambda light chain restricted) that are
clonally co-expressing = 1 B-cell marker (CD19, CD20, or CD23) and CD5.
2. Prolymphocytes may comprise = 55% of blood lymphocytes.
3. Presence of = 5 x 10^9 B lymphocytes/L (5000/µL) in the peripheral blood (at any
point since initial diagnosis).
4. Must have documented CD20-positive CLL.
5. Active disease meeting = 1 of the following IWCLL 2008 criteria for requiring
treatment:
1. Evidence of progressive marrow failure as manifested by the development of, or
worsening of, anemia (hemoglobin < 10 g/dL) and/or thrombocytopenia (platelets <
100,000/µL).
2. Massive (i.e., = 6 cm below the left costal margin), progressive, or symptomatic
splenomegaly.
3. Massive nodes (i.e., = 10 cm in the longest diameter), progressive, or
symptomatic lymphadenopathy.
4. Progressive lymphocytosis with an increase of > 50% over a 2-month period or a
LDT of < 6 months. LDT may be obtained by linear regression extrapolation of ALC
obtained at intervals of 2 weeks over an observation period of 2 to 3 months. In
subjects with initial blood lymphocyte counts of < 30 x 10^9/L (30,000/µL), LDT
should not be used as a single parameter to define indication for treatment. In
addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL
(e.g., infections) should be excluded.
5. Autoimmune anemia and/or thrombocytopenia that is poorly responsive to standard
therapy.
6. Constitutional symptoms documented in the subject's chart with supportive
objective measures, as appropriate, defined as = 1 of the following
disease-related symptoms or signs:
i. Unintentional weight loss = 10% within the previous 6 months before screening.
ii. Significant fatigue (ECOG performance score 2; inability to work or perform usual
activities).
iii. Fevers higher than 100.5°F or 38.0°C for = 2 weeks before screening without
evidence of infection.
iv. Night sweats for > 1 month before screening without evidence of infection.
6. Meet the following laboratory parameters:
1. ANC = 750 cells/µL (0.75 x 10^9/L), or = 500 cells/µL (0.50 x 10^9/L) in subjects
with documented bone marrow involvement, and independent of growth factor support
7 days before assessment.
2. Platelet count = 50,000 cells/µL (50 x 10^9/L), or = 30,000 cells/µL (30 x
10^9/L) in subjects with documented bone marrow involvement, and without
transfusion support 7 days before assessment. Subjects with transfusion-dependent
thrombocytopenia are excluded. If an Investigator has chosen
bendamustine/rituximab as the Arm B treatment, platelets must be = 75,000
cells/µL (75 x 10^9/L).
3. Serum AST and ALT = 2.0 x ULN.
4. Total bilirubin = 1.5 x ULN.
5. Estimated creatinine clearance of = 30 mL/min, calculated using the formula of
Cockcroft and Gault [(140-Age) • Mass (kg)/(72 • creatinine mg/dL); multiply by
0.85 if female].
7. Must have received = 1 prior systemic therapies for CLL. Note: Single-agent steroids
or localized radiation are not considered a prior line of therapy. If a single-agent
anti-CD20 antibody was previously administered, subjects must have received = 2 doses.
8. Women who are sexually active and can bear children must agree to use highly effective
forms of contraception while on the study and for 2 days after the last dose of
acalabrutinib, 90 days after the last dose of idelalisib, 6 months after the last dose
of bendamustine, or 12 months after the last dose of rituximab, whichever is longer.
Highly effective forms of contraception are defined in Section 9.2.5.
9. Men who are sexually active and can beget children must agree to use highly effective
forms of contraception during the study and for 90 days after the last dose of
idelalisib, 6 months after the last dose of bendamustine, or 12 months after the last
dose of rituximab, whichever is longer. Highly effective forms of contraception are
defined in Section 9.2.5.
10. Men must agree to refrain from sperm donation during the study and for 90 days after
the last dose of idelalisib, 6 months after the last dose of bendamustine, or 12
months after the last dose of rituximab, whichever is longer.
11. Willing and able to participate in all required evaluations and procedures in this
study protocol, including swallowing capsules without difficulty.
12. Ability to understand the purpose and risks of the study and provide signed and dated
informed consent and authorization to use protected health information (in accordance
with national and local patient privacy regulations).
Query!
Minimum age
No limit
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Known CNS lymphoma or leukemia.
2. Known prolymphocytic leukemia or history of, or currently suspected, Richter's
syndrome.
3. Uncontrolled AIHA or ITP defined as declining hemoglobin or platelet count secondary
to autoimmune destruction within the screening period or requirement for high doses of
steroids (> 20 mg daily of prednisone or equivalent).
4. Prior exposure to a BCL-2 inhibitor (e.g., venetoclax/ABT-199) or a BCR inhibitor
(e.g., BTK inhibitors or PI3K inhibitors). Prior bendamustine is allowed if
Investigator's choice for treatment in Arm B is idelalisib with rituximab.
Bendamustine retreatment is allowed if the prior response to bendamustine lasted > 24
months.
5. Received any chemotherapy, external beam radiation therapy, anticancer antibodies, or
investigational drug within 30 days before first dose of study drug.
6. Corticosteroid use > 20 mg daily prednisone equivalent within 1 week before first dose
of study drug, except as indicated for other medical conditions such as inhaled
steroid for asthma, topical steroid use, or as premedication for administration of
study drug or contrast. For example, subjects requiring steroids at daily doses > 20
mg prednisone equivalent systemic exposure daily, or those who are administered
steroids for leukemia control or white blood cell count lowering are excluded.
7. Prior radio- or toxin-conjugated antibody therapy.
8. Prior allogeneic stem cell transplant or prior autologous transplant within 6 months
of first dose of study drug(s) or presence of graft-vs-host disease or receiving
treatment for graft-vs-host disease.
9. Major surgical procedure within 30 days of first dose of study drug. Note: If a
subject had major surgery, they must have recovered adequately from any toxicity
and/or complications from the intervention before the first dose of study drug.
10. History of prior malignancy except for the following:
1. Malignancy treated with curative intent and with no evidence of active disease
present for more than 2 years before screening and felt to be at low risk for
recurrence by treating physician.
2. Adequately treated lentigo maligna melanoma without current evidence of disease
or adequately controlled nonmelanomatous skin cancer.
3. Adequately treated carcinoma in situ without current evidence of disease.
11. Significant cardiovascular disease such as uncontrolled or untreated symptomatic
arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart
Association Functional Classification, or QTc > 480 msec (calculated using
Fridericia's formula: QT/RR^0.33) at screening. Exception: Subjects with controlled,
asymptomatic atrial fibrillation during screening are allowed to enroll on study.
12. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or
resection of the stomach, or extensive small bowel resection that is likely to affect
absorption, symptomatic inflammatory bowel disease, or partial or complete bowel
obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
13. Received a live virus vaccination within 28 days of first dose of study drug.
14. Known history of infection with HIV or any uncontrolled active systemic infection
(e.g., bacterial, viral, or fungal). For study sites in Germany: active infection with
human immunodeficiency virus (seropositivity for HIV-1 or HIV-2 antibodies, and if
positive, reactivity against the HIV-specific p24 antigen).
15. Active CMV infection (active viremia as evidenced by positive polymerase chain
reaction [PCR] result for CMV DNA).
16. Serologic status reflecting active hepatitis B or C infection.
1. Subjects who are anti-HBc positive and who are surface antigen negative will need
to have a negative PCR result before randomization. Those who are HbsAg-positive
or hepatitis B PCR positive will be excluded.
2. Subjects who are hepatitis C antibody positive will need to have a negative PCR
result before randomization. Those who are hepatitis C PCR positive will be
excluded.
17. Ongoing, drug-induced liver injury, alcoholic liver disease, non-alcoholic
steatohepatitis, primary biliary cirrhosis, ongoing extrahepatic obstruction caused by
cholelithiasis, cirrhosis of the liver, or portal hypertension.
18. History of or ongoing drug-induced pneumonitis.
19. History of serious allergic reactions including anaphylaxis and toxic epidermal
necrolysis.
20. History of stroke or intracranial hemorrhage within 6 months before first dose of
study drug.
21. History of bleeding diathesis (e.g., hemophilia, von Willebrand disease).
22. Requires or receiving anticoagulation with warfarin or equivalent vitamin K
antagonists (e.g., phenprocoumon) within 7 days of first dose of study drug.
23. Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before
screening.
24. Requires treatment with a strong CYP3A inhibitor/inducer.
25. Requires treatment with proton-pump inhibitors (e.g., omeprazole, esomeprazole,
lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving
proton-pump inhibitors who switch to H2-receptor antagonists or antacids are eligible
for enrollment to this study.
26. Breast feeding or pregnant.
27. Concurrent participation in another therapeutic clinical trial.
28. Prothrombin time/INR or aPTT (in the absence of a Lupus anticoagulant) > 2.0 x ULN.
Exception: Subjects receiving warfarin are excluded, however, those receiving other
anticoagulant therapy who have a higher INR/aPTT may be permitted to enroll to this
study after discussion with the medical monitor.
29. History of confirmed progressive multifocal leukoencephalopathy (PML)
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
2/02/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
6/09/2027
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
310
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Adelaide
Query!
Recruitment hospital [2]
0
0
Research Site - Box Hill
Query!
Recruitment hospital [3]
0
0
Research Site - Frankston
Query!
Recruitment hospital [4]
0
0
Research Site - Geelong
Query!
Recruitment hospital [5]
0
0
Research Site - Gosford
Query!
Recruitment hospital [6]
0
0
Research Site - Hobart
Query!
Recruitment hospital [7]
0
0
Research Site - Kogarah
Query!
Recruitment hospital [8]
0
0
Research Site - Murdoch
Query!
Recruitment hospital [9]
0
0
Research Site - Nedlands
Query!
Recruitment hospital [10]
0
0
Research Site - South Brisbane
Query!
Recruitment hospital [11]
0
0
Research Site - Woodville
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [3]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [4]
0
0
3220 - Geelong
Query!
Recruitment postcode(s) [5]
0
0
2250 - Gosford
Query!
Recruitment postcode(s) [6]
0
0
7000 - Hobart
Query!
Recruitment postcode(s) [7]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [8]
0
0
6150 - Murdoch
Query!
Recruitment postcode(s) [9]
0
0
6009 - Nedlands
Query!
Recruitment postcode(s) [10]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [11]
0
0
5011 - Woodville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Georgia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Iowa
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kentucky
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Minnesota
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Nebraska
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New Jersey
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New York
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Texas
Query!
Country [13]
0
0
Austria
Query!
State/province [13]
0
0
Linz
Query!
Country [14]
0
0
Austria
Query!
State/province [14]
0
0
Salzburg
Query!
Country [15]
0
0
Austria
Query!
State/province [15]
0
0
Wels
Query!
Country [16]
0
0
Austria
Query!
State/province [16]
0
0
Wien
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Antwerpen
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Ghent
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Roeselare
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Yvoir
Query!
Country [21]
0
0
Bulgaria
Query!
State/province [21]
0
0
Pleven
Query!
Country [22]
0
0
Bulgaria
Query!
State/province [22]
0
0
Plovdiv
Query!
Country [23]
0
0
Bulgaria
Query!
State/province [23]
0
0
Stara Zagora
Query!
Country [24]
0
0
Bulgaria
Query!
State/province [24]
0
0
Vratsa
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Ontario
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
Calgary
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
Montreal
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
Ottawa
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Regina
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Saint John
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Toronto
Query!
Country [32]
0
0
Croatia
Query!
State/province [32]
0
0
Zadar
Query!
Country [33]
0
0
Croatia
Query!
State/province [33]
0
0
Zagreb
Query!
Country [34]
0
0
Czechia
Query!
State/province [34]
0
0
Brno
Query!
Country [35]
0
0
Czechia
Query!
State/province [35]
0
0
Novy Hradec Kralove
Query!
Country [36]
0
0
Czechia
Query!
State/province [36]
0
0
Olomouc
Query!
Country [37]
0
0
Czechia
Query!
State/province [37]
0
0
Ostrava Poruba
Query!
Country [38]
0
0
Czechia
Query!
State/province [38]
0
0
Plzen - Lochotin
Query!
Country [39]
0
0
Czechia
Query!
State/province [39]
0
0
Praha 10
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Bordeaux
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Brest
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Montpellier
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Nantes cedex 1
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Paris cedex 13
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Paris
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Perpignan
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Provence Alpes Cote D'Azur
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Rennes Cedex
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Rouen
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Aschaffenburg
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Dresden
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Munchen
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Mutlangen
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Ulm
Query!
Country [55]
0
0
Hong Kong
Query!
State/province [55]
0
0
HongKong
Query!
Country [56]
0
0
Hong Kong
Query!
State/province [56]
0
0
Pok Fu Lam
Query!
Country [57]
0
0
Hungary
Query!
State/province [57]
0
0
Budapest
Query!
Country [58]
0
0
Hungary
Query!
State/province [58]
0
0
Debrecen
Query!
Country [59]
0
0
Hungary
Query!
State/province [59]
0
0
Gyula
Query!
Country [60]
0
0
Hungary
Query!
State/province [60]
0
0
Kaposvár
Query!
Country [61]
0
0
Israel
Query!
State/province [61]
0
0
Ashkelon
Query!
Country [62]
0
0
Israel
Query!
State/province [62]
0
0
Haifa
Query!
Country [63]
0
0
Israel
Query!
State/province [63]
0
0
Jerusalem
Query!
Country [64]
0
0
Israel
Query!
State/province [64]
0
0
Kfar Saba
Query!
Country [65]
0
0
Israel
Query!
State/province [65]
0
0
Nahariya
Query!
Country [66]
0
0
Israel
Query!
State/province [66]
0
0
Petah Tikvah
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Aviano
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Bergamo
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Brescia
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Firenze
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
Genova
Query!
Country [72]
0
0
Italy
Query!
State/province [72]
0
0
Meldola
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
Milano
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
Milan
Query!
Country [75]
0
0
Italy
Query!
State/province [75]
0
0
Modena
Query!
Country [76]
0
0
Korea, Republic of
Query!
State/province [76]
0
0
Busan
Query!
Country [77]
0
0
Korea, Republic of
Query!
State/province [77]
0
0
Daegu
Query!
Country [78]
0
0
Korea, Republic of
Query!
State/province [78]
0
0
Dong-gu
Query!
Country [79]
0
0
Korea, Republic of
Query!
State/province [79]
0
0
Gyeonggi-do
Query!
Country [80]
0
0
Korea, Republic of
Query!
State/province [80]
0
0
Incheon
Query!
Country [81]
0
0
Korea, Republic of
Query!
State/province [81]
0
0
Jeonju-si
Query!
Country [82]
0
0
Korea, Republic of
Query!
State/province [82]
0
0
Seoul
Query!
Country [83]
0
0
New Zealand
Query!
State/province [83]
0
0
Addington
Query!
Country [84]
0
0
New Zealand
Query!
State/province [84]
0
0
Dunedin
Query!
Country [85]
0
0
New Zealand
Query!
State/province [85]
0
0
Palmerston North
Query!
Country [86]
0
0
New Zealand
Query!
State/province [86]
0
0
Tauranga
Query!
Country [87]
0
0
Poland
Query!
State/province [87]
0
0
Bialystok
Query!
Country [88]
0
0
Poland
Query!
State/province [88]
0
0
Bydgoszcz
Query!
Country [89]
0
0
Poland
Query!
State/province [89]
0
0
Gdansk
Query!
Country [90]
0
0
Poland
Query!
State/province [90]
0
0
Kraków
Query!
Country [91]
0
0
Poland
Query!
State/province [91]
0
0
Lodz
Query!
Country [92]
0
0
Poland
Query!
State/province [92]
0
0
Lublin
Query!
Country [93]
0
0
Poland
Query!
State/province [93]
0
0
Woj. Podkarpackie
Query!
Country [94]
0
0
Russian Federation
Query!
State/province [94]
0
0
Novosibirsk
Query!
Country [95]
0
0
Russian Federation
Query!
State/province [95]
0
0
Obninsk
Query!
Country [96]
0
0
Russian Federation
Query!
State/province [96]
0
0
Penza
Query!
Country [97]
0
0
Russian Federation
Query!
State/province [97]
0
0
Ryazan
Query!
Country [98]
0
0
Russian Federation
Query!
State/province [98]
0
0
Sochi
Query!
Country [99]
0
0
Russian Federation
Query!
State/province [99]
0
0
St. Petersburg
Query!
Country [100]
0
0
Russian Federation
Query!
State/province [100]
0
0
Tula
Query!
Country [101]
0
0
Russian Federation
Query!
State/province [101]
0
0
Volgograd
Query!
Country [102]
0
0
Russian Federation
Query!
State/province [102]
0
0
Yaroslavl
Query!
Country [103]
0
0
Russian Federation
Query!
State/province [103]
0
0
Yekaterinburg
Query!
Country [104]
0
0
Singapore
Query!
State/province [104]
0
0
SGP
Query!
Country [105]
0
0
Slovakia
Query!
State/province [105]
0
0
Bratislava
Query!
Country [106]
0
0
Slovakia
Query!
State/province [106]
0
0
Kosice
Query!
Country [107]
0
0
Spain
Query!
State/province [107]
0
0
Badalona
Query!
Country [108]
0
0
Spain
Query!
State/province [108]
0
0
Madrid
Query!
Country [109]
0
0
Spain
Query!
State/province [109]
0
0
Majadahonda
Query!
Country [110]
0
0
Spain
Query!
State/province [110]
0
0
Salamanca
Query!
Country [111]
0
0
Spain
Query!
State/province [111]
0
0
Santander
Query!
Country [112]
0
0
Spain
Query!
State/province [112]
0
0
Valencia
Query!
Country [113]
0
0
Sweden
Query!
State/province [113]
0
0
Goeteborg
Query!
Country [114]
0
0
Sweden
Query!
State/province [114]
0
0
Lulea
Query!
Country [115]
0
0
Sweden
Query!
State/province [115]
0
0
Stockholm
Query!
Country [116]
0
0
Taiwan
Query!
State/province [116]
0
0
Hualien
Query!
Country [117]
0
0
Taiwan
Query!
State/province [117]
0
0
Tainan
Query!
Country [118]
0
0
Taiwan
Query!
State/province [118]
0
0
Taipei
Query!
Country [119]
0
0
Ukraine
Query!
State/province [119]
0
0
Cherkasy
Query!
Country [120]
0
0
Ukraine
Query!
State/province [120]
0
0
Dnipropetrovsk
Query!
Country [121]
0
0
Ukraine
Query!
State/province [121]
0
0
Ivano-Frankivsk
Query!
Country [122]
0
0
Ukraine
Query!
State/province [122]
0
0
Khmelnytsky
Query!
Country [123]
0
0
Ukraine
Query!
State/province [123]
0
0
Kyiv
Query!
Country [124]
0
0
Ukraine
Query!
State/province [124]
0
0
Zhytomir
Query!
Country [125]
0
0
United Kingdom
Query!
State/province [125]
0
0
Birmingham
Query!
Country [126]
0
0
United Kingdom
Query!
State/province [126]
0
0
Cambridge
Query!
Country [127]
0
0
United Kingdom
Query!
State/province [127]
0
0
Canterbury
Query!
Country [128]
0
0
United Kingdom
Query!
State/province [128]
0
0
Leicester
Query!
Country [129]
0
0
United Kingdom
Query!
State/province [129]
0
0
London
Query!
Country [130]
0
0
United Kingdom
Query!
State/province [130]
0
0
Maidstone
Query!
Country [131]
0
0
United Kingdom
Query!
State/province [131]
0
0
Manchester
Query!
Country [132]
0
0
United Kingdom
Query!
State/province [132]
0
0
Southampton
Query!
Country [133]
0
0
United Kingdom
Query!
State/province [133]
0
0
Wolverhampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Acerta Pharma BV
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in
combination with idelalisib or bendamustine in previously treated subjects with chronic
lymphocytic leukemia (CLL).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02970318
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Acerta Clinical Trials
Query!
Address
0
0
1-888-292-9613;
[email protected]
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02970318
Download to PDF